Appropriate Use of Idarucizumab for Dabigatran Reversal According to the International Society on Thrombosis and Hemostasis and French Working Group on Perioperative Hemostasis: A French Retrospective Study

Affiliations

• ¹ Université de Paris, Innovative Therapies in Hemostasis, INSERM; Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux de Paris, Centre-Université de Paris (APHP-CUP), 75015, Paris, France.
• ² Université de Paris, PARCC, INSERM; Emergency Department, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris (APHP-CUP), 75015, Paris, France.
• ³ Université de Paris, Innovative Therapies in Hemostasis, INSERM; Département de Pharmacovigilance, Assistance Publique Hôpitaux de Paris, Centre-Université de Paris (APHP-CUP), 75015, Paris, France.
• ⁴ Université de Paris, Innovative Therapies in Hemostasis, INSERM; Hematology Department and Biosurgical Research Lab, (Carpentier Foundation) Assistance Publique Hôpitaux de Paris, Centre-Université de Paris (APHP-CUP), 75015, Paris, France; F-CRIN INNOVTE, Saint-Étienne, France.